

Haematologica
HAEMATOL/2019/238634
Version 3

Immune reconstitution and associated infections following
axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel S. Krivenko, Victoria Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chavez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien D. Liu, Javier Pinilla-Ibarz, Bijal D. Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai R. Dholaria, Michael D. Jain, and Frederick L. Locke

Disclosures: Christina Bachmeier: Advisory for Kite/Gilead. Julio C. Chavez: Advisory for Kite/Gilead, Novartis, Bayer, Genetech; Speaker Bureau for Genetech. Bijal D. Shah: Consultancy for Celgene/Juno, Adaptive, Kite/Gilead, Novartis, Pharmacyclics, Spectrum/Acroteca and AstraZeneca. Research funding from Jazz and Incyte. Javier Pinilla-Ibarz: Consultancy for Takeda, Abbvie, Janssen, Novartis, Gilead and Teva. Marco L Davila: Research funding from Celgene, Novartis, Atara; Other financial support from Novartis, Precision Biosciences, Celyad, Bellicum, GlaxoSmithKline; Stock options from Precision Biosciences, Adaptive Biotechnologies, Anixa Biosciences. Frederick L. Locke: Consultant for Cellular Biomedicine Group, Inc.; Scientific Advisor for Kite/Gilead, Novartis. Michael D. Jain: Consultant for Kite/Gilead and Novartis.

Contributions: MDJ and FLL designed and supervised the research. JML, EZ, CAB, GSK, VL and DN collected and analyzed data. GG, BC and JK provided statistical analysis. JCC, AB, FK, AL, TN, HDL, JP, BDS, RF, AEC, MLD and BRD provided patient information and data. All authors contributed to the writing of the manuscript.